Company / Free Cash Flow
BioNexus Gene Lab Corp Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$1.9M
FY2025
5-year range
-$2.3M / $551.8K
FY2021-FY2025
Trend
+19.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$2M.
Based on SEC 10-K filings.
-$2M in FY2025.
Improved from -$2M to -$2M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 19.2% year-over-year.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.9M | +19.2% |
| FY2024 | -$2.3M | -17.7% |
| FY2023 | -$2.0M | -457.3% |
| FY2022 | $551.8K | +9098.6% |
| FY2021 | $6.0K | -95.4% |
| FY2020 | $131.1K | +157.0% |
| FY2019 | -$230.1K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026